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Malignant pericardial mesothelioma (MPerM) is anextremely rare and lethal cardiac tumor.1 The prog-
nosis is poor, and treatments such as surgery and radio-
therapy have not demonstrated an impact on disease pro-
gression. We report a case of MPerM with response to
chemotherapy.
CASE REPORT
A 61-year-old woman was referred to our hospital
because of dyspnea on exertion. A computed tomography
(CT) scan of the chest showed diffuse thickening of the
pericardium (Figures 1A, B). The presence of fluid in the
right pleural cavity was apparent, but tumor formation was
not found on the pleura or the lung. Cardiac ultrasonogra-
phy showed impaired left ventricular wall motion and
dilatation of the inferior vena cava with loss of respiratory
fluctuation. Cytologic examination of the pleural fluid was
negative (class II). An open-chest, pericardial biopsy was
performed without pleural inspection or biopsy. Micro-
scopic examination of the specimen showed proliferation
of mesothelial cells with nuclear atypicality consistent
with malignant mesothelioma (Figure 2A). Immunohisto-
chemical analyses revealed that the cells were calretinin
positive, epithelial membrane antigen positive, and carci-
noembryonic antigen negative (Figures 2B–D). These find-
ings confirmed the diagnosis of malignant mesothelioma.
Systemic chemotherapy consisting of carboplatin (AUC 
5, day 1) and pemetrexed (500 mg/m2, day 1) was initiated,
and regression of the pericardial thickening was exhibited
after the second course (Figure 1C). The dyspnea on
exertion was relieved. Six cycles of the chemotherapy
were given; however, 6 months later, pleural fluid accu-
mulated in the left cavity and mesothelioma cells were
detected in the fluid. As salvage chemotherapy, irinotecan
hydrochloride (60 mg/m2, days 1, 8, and 15) was admin-
istered. A CT scanning of the chest after the second course
showed regression of the pericardial tumor and decrease in
the amount of pleural fluid. Two months later, the patient
died of disease progression, 18 months after the diagnosis.
Autopsy was not allowed.
DISCUSSION
MPerM is a rare tumor, which has a reported inci-
dence of 0.0022% in an autopsy series of 500,000 case
studies.2 A clinical sign is constrictive pericarditis. Car-
diac ultrasonography may reveal an effusion or myocardial
mass. A CT scanning of the chest may also show pericar-
dial effusion, thickening of the pericardium, or pericardial
mass formation.1 However, these findings are nonspecific.
In the current case, the CT scanning showed diffuse
thickening of the pericardium, indicating constrictive peri-
carditis, but no tumor formation. MPerM should be noted
as one cause of unexplained constrictive pericarditis.
The prognosis for MPerM is poor, and the clinical
course is progressive. No clinical trial has yet been con-
ducted and standard treatment has not yet been established.
Recently, pemetrexed, a multitargeted antifolate, has dem-
onstrated modest activity against malignant pleural me-
sothelioma in combination with cisplatin3 or carboplatin.4
Irinotecan was also reported to demonstrate a modest
activity against pleural mesothelioma in a clinical trial.5
There is no previous report that these regimens were
applied to MPerM, so the current case might be the first
report that these regimens have shown clinical activity
against MPerM.
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In conclusion, MPerM is an extremely rare neo-
plasm. A combination chemotherapy consisting of carbo-
platin and pemetrexed or irinotecan monotherapy would be
a favorable treatment option against MPerM.
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FIGURE 1. CT scan of the chest
at the time of diagnosis showing
diffuse thickening of the pericar-
dium; (A) sagittal and (B) horizon-
tal views. After administration of
chemotherapy consisting of carbo-
platin and pemetrexed, (C) regres-
sion of the pericardial thickening
was exhibited.
FIGURE 2. A, Microscopic examination of the biopsy speci-
men showed proliferation of mesothelial cells with nuclear
atypicality consistent with malignant mesothelioma (hematoxy-
lin-eosin, 40). B, Immunohistochemical analysis revealed posi-
tive expression of calretinin (20), (C) epithelial membrane
antigen (20), and (D) negative expression of CEA (20).
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